Corxel, an obesity drugmaker, to go public via SPAC deal
Source: BioPharma Dive - Latest News
Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.